Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: BMSystems will be participating to Neurology Drug Development Europe and Polepharma (the N°1 pharmaceutical cluster in Europe) events: Alzheimer's Disease recurrent failures: A causal CADI™ model explains 14 key disease components!
      
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: www.gemma-project.eu for the World Autism Awareness Day.
     
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

  • 2018: PRESSE-RELEASE: L’Association Française du Syndrome de Fatigue Chronique (AFSC) change les règles du jeu et s’associe à Bio-Modeling Systems pour développer et valider un modèle explicatif et thérapeutique de l'EM/SFC (CFS/ME).

  • 2018: PRESS-RELEASE: Paris October 10, 2108: Bio-Modeling Systems, with its operational CADI™ Discovery platform, is the Integrative Biology partner of GEMMA (autism & microbiota) project selected for €14.2M H2020 funding by the European Commission to identify potential targets for the personalized treatment and prevention of Autism Spectrum Disorderss

  • 2018: PRESS-RELEASE: Paris 10 Octobre 2108: Bio-Modeling Systems, avec sa plateforme opérationnelle CADI™ Discovery est le partenaire « Biologie Intégrative » du  programme GEMMA (autisme & microbiote) sélectionné par la Commission européenne pour un financement H2020 de 14,2 millions d'euros afin d'identifier des cibles potentielles pour le traitement personnalisé et la prévention des troubles du spectre autistique

  • 2018: ANNOUNCEMENT: Paris September 4, 2018: How CADI Discovery, invented in 2004,  successfully addressed the "Garbage in Garbage out" Law of every Data Processing explained in Current Opinion in Pharmacology:  How scientific literature analysis yields innovative therapeutic hypothesis through integrative iterations.
     
  • 2018: PRESS-RELEASE: Paris  July17, 2018: World's first: The French Chronic Fatigue Syndrome Association decides to clinically evaluate the ME/CFS pathogenesis model produced by Bio-Modeling System.s

  • 2018: ANNOUNCEMENT: Paris June 19-20, 2018: BMSystems invited to the Microbiotes conference organized by Adebiotech to present its microbiota vision and CADI Discovery programs. 

  • 2018: ANNOUNCEMENT: Paris June 14, 2018: BMSystems invited to the Connected Health Conference organized by ANRT to present its Real life data strategy with its "patients & HCP digital pathways" partner Bolero.

  • 2018: ANNOUNCEMENT: Paris March 13-14, 2018: BMSystems invited to the Epigentic conference organised by Adebiotech to present its CADI Discovery program EPIGEN-DIAB with the Centrer of excelllence in Epigenetic in India.
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

BMSystems know-how and Technologies 

1-CADI™ (Computer-Augmented Deductive Intelligence)  proprietary methodologies and tools

2-CADI™ Global discovery & validation process exploiting Smart Data
(contextualized, with patients based lines, related to mechanisms data)

BMSystems Technologies (non-confidential)

  • Computer-Assisted Deductive Integration (CADI™) proprietary methodologies and tools.
  • CADI™ Search (data acquisition & mining).
  • CADI™ Architect (data organization & structuring).
  • CADI™ Fiber-N (integrative engine).
  • CADI™ View (model representation & visualization).
  • TAPE Patent: WO/2008/093010- December 2006. A technology allowing to rapidly & simultaneously introduce defined densities of random mutations in any number of selected regions within a gene while conserving intact any number of defined coding domains in this same gene (applicable to all proteins, including antibodies, enzymes, etc..).
  • AB-ACCUS patent: WO/2008/093009 - December 2006. A recombination technology allowing the rapid & efficient production of phage banks in which every individual differs from all others for any number of selected genes or other sequences.
  • RIPh patent: PCT/FR2010/050796 – May 2009. A methodology allowing to reversibly immobilize an obligate lytic phage within its bacterial host and to then extensively modify its genome without adversely affecting the phage's replicative ability.
  • CNS copatent: WO/2010/029131 - September, 2008. Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

 

 

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers